Sign In
Buy QTTB
$11.88
-0.770 (-6.09%)
At Close: Jun 23, 2026
New Strong Buy Stocks for March 13th
06:20am, Friday, 13'th Mar 2026
TBLA, MCY, DXPE, CABO and QTTB have been added to the Zacks Rank #1 (Strong Buy) List on March 13th, 2026.
Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update
06:59am, Tuesday, 10'th Mar 2026
-- Completed enrollment in Part B of SIGNAL-AA Phase 2a clinical trial and increased trial size to 33 patients based on patient demand; 36-week topline data readout expected in mid-2026 -- -- Complete
Q32 Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
06:59am, Wednesday, 18'th Feb 2026
WALTHAM, Mass., Feb. 18, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and
Q32 Bio Announces $10.5 Million Registered Direct Offering
06:59am, Tuesday, 17'th Feb 2026
WALTHAM, Mass., Feb. 17, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and ot
Dow Dips 200 Points; Q32 Bio Shares Jump
09:58am, Monday, 01'st Dec 2025
U.S. stocks traded lower this morning, with the Dow Jones falling around 200 points on Monday.
Why Is Small-Cap Q32 Bio Stock Soaring On Monday?
09:43am, Monday, 01'st Dec 2025
Q32 Bio Inc. (NASDAQ: QTTB) stock is trading higher on Monday, with a session volume of 70.56 million compared to the average volume of 217.704 thousand as per data from Benzinga Pro.
Q32 Bio Sells Complement Inhibitor ADX-097
07:00am, Monday, 01'st Dec 2025
-- Asset sale further enables Company's strategic focus on advancing bempikibart for alopecia areata -- -- $12 million in upfront and guaranteed near-term milestone payments expected to extend cash ru
Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
06:59am, Thursday, 13'th Nov 2025
-- Completed enrollment in Part B of SIGNAL-AA Phase 2a clinical trial and increased trial size to 33 patients based on patient demand; topline data readout expected in mid-2026 -- -- Dosing of patie
Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata
06:59am, Tuesday, 21'st Oct 2025
-- SIGNAL-AA Part B exceeded target enrollment based on demand from patients; trial size increased to 33 patients -- WALTHAM, Mass. , Oct. 21, 2025 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bi
Q32 Bio to Participate in the 2025 Wells Fargo Healthcare Conference
06:59am, Thursday, 28'th Aug 2025
WALTHAM, Mass. , Aug. 28, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and
Q32 Bio (QTTB) Q2 Loss Drops 45%
02:03pm, Wednesday, 06'th Aug 2025
Q32 Bio (QTTB) Q2 Loss Drops 45%
Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update
06:59am, Wednesday, 06'th Aug 2025
-- Dosing of patients in Part A open-label extension (OLE) and Part B of SIGNAL-AA ongoing; SIGNAL-AA Part B topline data readout on-track for 1H'26 -- -- Strengthened leadership team with appointment
Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer
06:59am, Wednesday, 25'th Jun 2025
-- Dr. Sipos is an immunologist and seasoned Immunology and Inflammation (I&I) drug developer, with over 25 years of clinical development and medical affairs leadership experience -- WALTHAM, Mass. ,
19,009 Shares in Q32 Bio Inc. (NASDAQ:QTTB) Acquired by Squarepoint Ops LLC
03:34am, Wednesday, 11'th Jun 2025
Squarepoint Ops LLC bought a new position in shares of Q32 Bio Inc. (NASDAQ:QTTB – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and
Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update
06:59am, Thursday, 08'th May 2025
-- First patient dosed in SIGNAL-AA Phase 2a Part B; topline data readout on-track for 1H'26 -- -- First patient dosed in SIGNAL-AA Part A open-label extension (OLE) -- -- Fast Track designation (FTD)
